Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment.
作者信息
Manouchehri Navid, Stüve Olaf
机构信息
Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Neurology Section, VA North Texas Health Care System, Medical Service, 4500 South Lancaster Rd., Dallas, TX 75216, USA Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9036, USA.
出版信息
Ther Adv Neurol Disord. 2021 Feb 1;14:1756286421990500. doi: 10.1177/1756286421990500. eCollection 2021.
Abstract
摘要
相似文献
1
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment.奥瑞珠单抗是否应用于非活动性原发性进行性多发性硬化症？是时候重新评估了。
Ther Adv Neurol Disord. 2021 Feb 1;14:1756286421990500. doi: 10.1177/1756286421990500. eCollection 2021.
2
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.奥瑞珠单抗治疗原发性进展型多发性硬化症的 ORATORIO 试验的长期随访：正在进行的随机、安慰剂对照、3 期试验开放标签扩展的事后分析。
Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29.
3
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.奥瑞珠单抗与安慰剂治疗原发性进行性多发性硬化症。
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
4
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验：来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
5
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.系统评价和网络荟萃分析比较奥瑞珠单抗与其他治疗复发型多发性硬化症的药物。
Mult Scler Relat Disord. 2019 Apr;29:55-61. doi: 10.1016/j.msard.2018.12.040. Epub 2019 Jan 2.
6
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.一项评估奥瑞珠单抗在德国真实世界多发性硬化症队列中长期安全性和有效性的非干预性上市后研究的设计 - CONFIDENCE 研究方案。
BMC Neurol. 2020 Mar 14;20(1):95. doi: 10.1186/s12883-020-01667-7.
7
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.奥瑞珠单抗可减缓原发性进展型多发性硬化症患者上肢功能障碍的进展：来自 III 期随机 ORATORIO 试验的结果。
Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12.
8
Ocrelizumab for the treatment of multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.
9
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.奥瑞珠单抗：一种用于治疗复发缓解型和原发性进展型多发性硬化症的新型 B 细胞疗法。
Ann Pharmacother. 2018 May;52(5):473-483. doi: 10.1177/1060028017747635. Epub 2017 Dec 12.
10
Ocrelizumab: its efficacy and safety in multiple sclerosis.奥瑞珠单抗：其在多发性硬化症中的疗效与安全性。
Rev Neurol. 2018 Jun 16;66(12):423-433.
引用本文的文献
1
Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.进展性多发性硬化症：评估当前疗法并探索未来治疗策略。
Neurotherapeutics. 2025 Jul;22(4):e00601. doi: 10.1016/j.neurot.2025.e00601. Epub 2025 May 9.
2
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).奥瑞珠单抗治疗原发性进展型多发性硬化症的有效性：一项多中心、回顾性、真实世界研究（OPPORTUNITY）。
Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23.
3
Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.疾病修饰疗法在进展型多发性硬化症中的疗效以及免疫衰老如何解释其失败原因。
Front Neurol. 2022 Mar 31;13:854390. doi: 10.3389/fneur.2022.854390. eCollection 2022.
4
Choroid plexus volumetrics and brain inflammation in multiple sclerosis.多发性硬化症中的脉络丛容积测定与脑部炎症
Proc Natl Acad Sci U S A. 2021 Oct 5;118(40). doi: 10.1073/pnas.2115221118.
本文引用的文献
1
The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.多发性硬化症中炎症与神经退行性变的时间和因果关系。
Mult Scler. 2020 Jul;26(8):876-886. doi: 10.1177/1352458519886943. Epub 2019 Nov 4.
2
Clinical trials in multiple sclerosis: potential future trial designs.多发性硬化症的临床试验：未来可能的试验设计
Ther Adv Neurol Disord. 2019 May 13;12:1756286419847095. doi: 10.1177/1756286419847095. eCollection 2019.
3
Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.神经丝轻链：迈向多发性硬化症疾病生物标志物的重要一步。
Neurology. 2019 Mar 5;92(10):451-452. doi: 10.1212/WNL.0000000000007022. Epub 2019 Feb 8.
4
Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study.非洲肌萎缩侧索硬化症的临床特征和预后：TROPALS 研究。
J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):20-29. doi: 10.1136/jnnp-2018-318469. Epub 2018 Sep 21.
5
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.奥瑞珠单抗与安慰剂治疗原发性进行性多发性硬化症。
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
6
Defining the clinical course of multiple sclerosis: the 2013 revisions.多发性硬化症临床病程的定义：2013年修订版
Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
7
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.针对 CD20 的单克隆抗体的表位相互作用及其与功能特性的关系。
MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.
8
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.利妥昔单抗治疗原发性进行性多发性硬化症患者：一项随机双盲安慰剂对照多中心试验的结果
Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.
Zotero 插件